AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3043367 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 319
Study 3043367 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell vaccine
Number of subjects: 319
Study 30244028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified multifactorial treatment
Number of subjects: 160
Study 30244028 — intervention group
Group type: COMPARATOR
Intervention: Conventional multifactorial treatment
Number of subjects: 160
Study 30244028 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling urine 8‐oxoGuo level
Number of subjects: 160
Study 30244028 — intervention group
Group type: EXPERIMENTAL
Intervention: High urine 8‐oxoGuo levels
Number of subjects: 160
Study 27174405 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsplinted implants with ball attachment (BA)
Number of subjects: 30
Study 27174405 — intervention group
Group type: COMPARATOR
Intervention: Splinted implants with bar attachment (RA)
Number of subjects: 30
Study 25531996 — intervention group
Group type: EXPERIMENTAL
Intervention: L. reuteri (DSM 17938)
Number of subjects: 40
Study 25531996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22442102 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated email-based campaign promoting self-help behaviours
Number of subjects: 1326
Study 22442102 — intervention group
Group type: COMPARATOR
Intervention: General information about depression (Control)
Number of subjects: 1326
Study 21443093 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromoendoscopy with indigo carmine
Number of subjects: 130
Study 21443093 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 130
Study 17490972 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate protein (IP) group; 0.5 g protein x kg(‐1) x d(‐1)
Number of subjects: 21
Study 17490972 — intervention group
Group type: COMPARATOR
Intervention: Control group; 1.2 g protein x kg(‐1) x d(‐1)
Number of subjects: 21
Study 16137086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized titanium implants (TiUnite)
Number of subjects: 12
Study 12202088 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1.0 ng/ml effect site concentration)
Number of subjects: 9
Study 12202088 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 10469778 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell transfusions based on symptom-based guidelines (Group 1)
Number of subjects: 50
Study 10469778 — intervention group
Group type: COMPARATOR
Intervention: Red cell transfusions to maintain hematocrit above 40% (Group 2)
Number of subjects: 50
Study 10469778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 50
Study 10469778 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 50
Study 10469778 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 50
Study 8901853 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene and 25,000 IU retinyl palmitate (vitamin A) taken daily
Number of subjects: 18314
Study 1906634 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid producing bacteria (Lactobacillus acidophilus and Bifidobacterium bifidum) with 500 mg ampicillin t.i.d. for 7 days
Number of subjects: 20
Study 1906634 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 500 mg ampicillin t.i.d. for 7 days
Number of subjects: 20
Study 6319633 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Program (SMP) consisting of eight weekly one-hour sessions of relaxation response, imagery, and diaphragmatic breathing; caffeine intake reduction
Number of subjects: 30
Study 6319633 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 28944645 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA (9.6 g·day‐1) before exercise
Number of subjects: 15
Study 28944645 — intervention group
Group type: COMPARATOR
Intervention: BCAA (9.6 g·day‐1) after exercise
Number of subjects: 15
Study 28944645 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo before and after exercise)
Number of subjects: 15
Study 26979433 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 1 (sucrose:xylose = 10:1)
Number of subjects: 75
Study 26979433 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 2 (sucrose:xylose = 15:1)
Number of subjects: 75
Study 26979433 — intervention group
Group type: EXPERIMENTAL
Intervention: Test 3 (sucrose:xylose = 20:1)
Number of subjects: 75
Study 26979433 — intervention group
Group type: COMPARATOR
Intervention: Control (sucrose 50 g + deionized water 100 g)
Number of subjects: 75
Study 24439796 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted TKA
Number of subjects: 60
Study 24439796 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 60
Study 22741171 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-based intervention to optimize dietary vitamin E intake to 15 mg/day
Number of subjects: 43
Study 22741171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary advice)
Number of subjects: 43
Study 20625129 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 89
Study 20625129 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 89
Study 17352867 — intervention group
Group type: EXPERIMENTAL
Intervention: Yisui Shengxue Granule (YSSXG)
Number of subjects: 60
Study 17352867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15378384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar keratotomy with an incision width of 6 mm and a radial length of 1.5 mm
Number of subjects: 25
Study 15378384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamellar keratotomy
Number of subjects: 25
Study 11892639 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 1:200 000
Number of subjects: 133
Study 11892639 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 133
Study 10201586 — intervention group
Group type: EXPERIMENTAL
Intervention: First eye surgery
Number of subjects: 403
Study 10201586 — intervention group
Group type: EXPERIMENTAL
Intervention: Second eye surgery
Number of subjects: 403
Study 8643968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 combined with carboplatin (AUC 6)
Number of subjects: 41
Study 8643968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 225 mg/m2 combined with carboplatin (AUC 6)
Number of subjects: 41
Study 8643968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (various doses)
Number of subjects: 41
Study 8643968 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with carboplatin
Number of subjects: 41
Study 2177610 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 90
Study 481481 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan and prednisone (Group A)
Number of subjects: 364
Study 481481 — intervention group
Group type: COMPARATOR
Intervention: Melphalan, cyclophosphamide, carmustine, and prednisone in alternating schedule (Group B)
Number of subjects: 364
Study 481481 — intervention group
Group type: COMPARATOR
Intervention: Melphalan, cyclophosphamide, carmustine, and prednisone in concurrent schedule (Group C)
Number of subjects: 364
Study 481481 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (A, B, C)
Number of subjects: 364
Study 31912156 — intervention group
Group type: EXPERIMENTAL
Intervention: iCRAFT
Number of subjects: 94
Study 31912156 — intervention group
Group type: COMPARATOR
Intervention: Wait-list (WL)
Number of subjects: 94
Study 31131743 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-duration treatment (300 hours) with applied technology and motor learning.
Number of subjects: 31
Study 28333010 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-WBI (42.56 Gy/16 fractions + 10-12.5 Gy/4-5 fx boost)
Number of subjects: 287
Study 28333010 — intervention group
Group type: COMPARATOR
Intervention: CF-WBI (50 Gy/25 fx + 10-14 Gy/5-7 fx)
Number of subjects: 287
Study 28333010 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported cosmesis
Number of subjects: 287
Study 28333010 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-reported cosmesis
Number of subjects: 287
Study 25809877 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin 0.2 mg once daily
Number of subjects: 112
Study 25809877 — intervention group
Group type: EXPERIMENTAL
Intervention: solifenacin 5 mg once daily
Number of subjects: 112
Study 25809877 — intervention group
Group type: EXPERIMENTAL
Intervention: both tamsulosin and solifenacin
Number of subjects: 112
Study 25809877 — intervention group
Group type: COMPARATOR
Intervention: control group (A)
Number of subjects: 112
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir (VGCV) dosing appropriate for most patients
Number of subjects: 187
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk CMV serostatus (donor positive/recipient negative)
Number of subjects: 187
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin induction therapy
Number of subjects: 187
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mean tacrolimus trough concentration
Number of subjects: 187
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatinine clearance <60 mL/min
Number of subjects: 187
Study 24010993 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight >80 kg
Number of subjects: 187
Study 21383557 — intervention group
Group type: EXPERIMENTAL
Intervention: Anal fistula plug
Number of subjects: 60
Study 21383557 — intervention group
Group type: COMPARATOR
Intervention: Mucosal advancement flap
Number of subjects: 60
Study 19741042 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer‐assisted self‐interviewing (ACASI)
Number of subjects: 910
Study 19741042 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face interviewing (FTFI)
Number of subjects: 910
Study 19741042 — intervention group
Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 910
Study 19741042 — intervention group
Group type: COMPARATOR
Intervention: FTFI
Number of subjects: 910
Study 19741042 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA-positive participants
Number of subjects: 910
Study 17826341 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (5 mg/kg, 15 mg/kg, and 45 mg/kg)
Number of subjects: 48
Study 17826341 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone (high-dose)
Number of subjects: 48
Study 17826341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15036546 — intervention group
Group type: EXPERIMENTAL
Intervention: Low incentive condition (US$ 10 per test)
Number of subjects: 0
Study 15036546 — intervention group
Group type: EXPERIMENTAL
Intervention: High incentive condition (US$ 20 per test)
Number of subjects: 0
Study 15036546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluid test
Number of subjects: 0
Study 15036546 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair testing
Number of subjects: 0
Study 15036546 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine testing
Number of subjects: 0
Study 11753789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP) plus 5-fluorouracil and leucovorin (5-FU/LV)
Number of subjects: 0
Study 11753789 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil and leucovorin (5-FU/LV) alone
Number of subjects: 0
Study 11753789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP) in combination with 5-FU/LV
Number of subjects: 0
Study 11753789 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin (l-OHP)
Number of subjects: 0
Study 9735586 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session assertiveness training intervention
Number of subjects: 20
Study 9735586 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 20
Study 9028308 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (granulocyte colony‐stimulating factor) at a dosage of 5 micrograms/kg, starting the day after completion of the third cycle of chemotherapy.
Number of subjects: 0
Study 1723773 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 468
Study 1723773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 1723773 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased medical attention and care
Number of subjects: 468
Study 6752872 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen 600 mg/day
Number of subjects: 124
Study 6752872 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 300 mg/day
Number of subjects: 124
Study 6752872 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 124
Study 31800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 1672
Study 31800988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 1672
Study 31800988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1672
Study 27737436 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 545
Study 27737436 — intervention group
Group type: EXPERIMENTAL
Intervention: CapeOx and lapatinib with PPIs
Number of subjects: 545
Study 27737436 — intervention group
Group type: COMPARATOR
Intervention: No Proton Pump Inhibitors (PPIs)
Number of subjects: 545
Study 25575253 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive esophagectomy (MIE)
Number of subjects: 104
Study 25175658 — intervention group
Group type: EXPERIMENTAL
Intervention: fine particle beclomethasone (HFA‐BDP; Qvar Autohaler)
Number of subjects: 66
Study 25175658 — intervention group
Group type: COMPARATOR
Intervention: budesonide (DPI‐BUD; Pulmicort Turbohaler)
Number of subjects: 66
Study 22234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic altitude training
Number of subjects: 26
Study 22234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Live High:Train Low (LHTL) altitude training
Number of subjects: 26
Study 22234397 — intervention group
Group type: COMPARATOR
Intervention: Race Control
Number of subjects: 26
Study 22234397 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic and LHTL
Number of subjects: 26
Study 19717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 413
Study 19717347 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 413
Study 19717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment with stent
Number of subjects: 413
Study 19717347 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment with balloon angioplasty
Number of subjects: 413
Study 19717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Restenosis of 70% or more
Number of subjects: 413
Study 19717347 — intervention group
Group type: COMPARATOR
Intervention: No restenosis of 70% or more
Number of subjects: 413
Study 19717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking or history of smoking
Number of subjects: 413
Study 19717347 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate stenosis (50-69%) within 60 days after treatment
Number of subjects: 413
Study 16891124 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of impending movement
Number of subjects: 0
Study 16891124 — intervention group
Group type: COMPARATOR
Intervention: No awareness of impending movement
Number of subjects: 0
Study 15067694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonal THC (0.053 mg/kg)
Number of subjects: 8
Study 15067694 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous THC (0.053 mg/kg body weight)
Number of subjects: 8
Study 15067694 — intervention group
Group type: COMPARATOR
Intervention: Pulmonal Placebo
Number of subjects: 8
Study 12417538 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg twice daily for 30 days)
Number of subjects: 272
Study 12417538 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group for Cp-positive patients)
Number of subjects: 272
Study 12417538 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group for Cp-negative patients)
Number of subjects: 272
Study 9167520 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral prefrontal repetitive transcranial magnetic stimulation (80% motor threshold, 20 Hz/2 seconds per minute for 20 minutes)
Number of subjects: 12
Study 9167520 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 12
Study 9167520 — intervention group
Group type: COMPARATOR
Intervention: Midoccipital repetitive transcranial magnetic stimulation (control)
Number of subjects: 12
Study 9167520 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral prefrontal repetitive transcranial magnetic stimulation
Number of subjects: 12
Study 1337337 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF administration starting one day after chemotherapy for 7-10 days
Number of subjects: 0
Study 1337337 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF administration after high-dose chemotherapy
Number of subjects: 0
Study 1337337 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF administration after initial cycles of chemotherapy
Number of subjects: 0
Study 3990156 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin for early closure of ductus arteriosus
Number of subjects: 27
Study 30317146 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli consumption (200 g of cooked broccoli and 20 g of raw daikon radish per day)
Number of subjects: 18
Study 30317146 — intervention group
Group type: EXPERIMENTAL
Intervention: Broccoli consumption
Number of subjects: 18
Study 28780214 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful External Cephalic Version (ECV)
Number of subjects: 931
Study 28780214 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful External Cephalic Version (ECV) in multiparous women
Number of subjects: 931
Study 28780214 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Cephalic Version (SCV)
Number of subjects: 931
Study 27139019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack therapy applied intermittently over the masseteric region post-surgery.
Number of subjects: 0
Study 27139019 — intervention group
Group type: COMPARATOR
Intervention: No ice pack therapy (Control Group B).
Number of subjects: 0
Study 24458443 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 48
Study 24458443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 22922806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 7
Study 22922806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration plus Squatting (WBV+S)
Number of subjects: 7
Study 20431422 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAI (continuous regional arterial infusion) with nafamostat mesylate 240 mg/d and imipenem 1 g/d for 5 days, followed by imipenem intravenously (0.5 g every 8 hours) for 9 days
Number of subjects: 78
Study 20431422 — intervention group
Group type: COMPARATOR
Intervention: Non-CRAI group receiving imipenem (0.5 g every 8 hours) intravenously for 14 days
Number of subjects: 78
Study 20431422 — intervention group
Group type: EXPERIMENTAL
Intervention: CRAI group
Number of subjects: 78
Study 20431422 — intervention group
Group type: COMPARATOR
Intervention: Non-CRAI group
Number of subjects: 78
Study 19089223 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment in Class II/1 malocclusion patients (group T)
Number of subjects: 34
Study 19089223 — intervention group
Group type: COMPARATOR
Intervention: Class I malocclusion patients (group C - control)
Number of subjects: 34
Study 15634808 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative inpatient intervention program involving patient education and providing a list of questions for the primary care physician.
Number of subjects: 80
Study 15634808 — intervention group
Group type: COMPARATOR
Intervention: Control group received a brochure describing methods for preventing falls.
Number of subjects: 80
Study 11808967 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2-specific inhibitor and traditional NSAID therapy
Number of subjects: 3907
Study 10521728 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovaginal ultrasonographic assessment
Number of subjects: 102
Study 10521728 — intervention group
Group type: COMPARATOR
Intervention: Transperineal ultrasonographic assessment
Number of subjects: 102
Study 7853952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 IU unfractionated heparin
Number of subjects: 39
Study 7853952 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 anti-Xa IU low-molecular-weight heparin
Number of subjects: 39
Study 7853952 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 39
Study 1992028 — intervention group
Group type: EXPERIMENTAL
Intervention: 1073 MBq iodine-131
Number of subjects: 63
Study 1992028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3700 MBq iodine-131
Number of subjects: 63
Study 6344270 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (Biltricide; Bayer‐Miles) at a dosage of 40 mg/kg body weight
Number of subjects: 137
Study 6344270 — intervention group
Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 137
Study 29431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindergartens with expenditures for food and beverages included in parental fees
Number of subjects: 73
Study 29431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindergartens where parents paid a monthly fee of 251 NOK or more
Number of subjects: 73
Study 29431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindergartens where employees paid a monthly fee to eat at work
Number of subjects: 73
Study 29431028 — intervention group
Group type: EXPERIMENTAL
Intervention: Kindergartens with written guidelines for food and beverages offered
Number of subjects: 73
Study 30303900 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ulipristal acetate
Number of subjects: 432
Study 30303900 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ulipristal acetate
Number of subjects: 432